Panel Discussion: Vaccines, Intellectual Property, and Global Equity

The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2.  The COVID-19 pandemic has shined a spotlight on the role of intellectual property in modern medicine and on the complex social questions surrounding a system that grants exclusive rights over life-or-death products. On the one hand, there … Continue reading “Panel Discussion: Vaccines, Intellectual Property, and Global Equity”

A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines

Issue The United States and other wealthy nations have access to plenty of COVID-19 vaccine doses and thus are beginning to get the pandemic under control, while less affluent countries do not have access to adequate doses and are still struggling with rising cases. In October 2020, India and South Africa proposed addressing this problem … Continue reading “A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines”

WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies

By Yogesh Pai Since October 2020, India and South Africa, joined by two-thirds of the WTO Members (African Group, LDCs and most of developing world) have been actively pursuing other developed country Members to agree to their request to waive global intellectual property (IP) rules. The waiver asserts that by suspending IP protection for COVID-19 … Continue reading “WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies”